August Bioservices, a pharmaceutical contract development and manufacturing organization (CDMO) providing drug discovery, development and pharmaceutical manufacturing services, today announced that it secured $65 million in Series B funding led by Oak HC/FT, who led the Series A in July 2020. This round includes participation from existing investor, Polaris Partners.

August Bioservices is a high-tech, growth-focused, and innovative provider of Contract Research, Development and Manufacturing services, that plays a crucial role in the global pharmaceutical industry supply chain. August Bioservices partners with biopharmaceutical and biotech companies to provide a wide array of services that help to accelerate the advancement of novel therapeutics along the drug development pathway.